Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 68071-2824

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 68071-2824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 2824 9)

Pdp (68071 2824 9)
This text appears to be a detailed medication label for Atorvastatin Calcium tablets. Each film-coated tablet contains Atorvastatin Calcium, equivalent to 20mg of Atorvastatin. The medication is described as an elliptical white tablet with 'RX 828' debossed on one side and plain on the other side. The label provides information about the National Drug Code (NDC) for the product, the lot number, expiration date, and manufacturer details. It also includes a warning to keep the medication out of reach of children and advice to store it at a controlled temperature of 68-77°F. For medical advice about side effects, individuals are instructed to contact their doctor or report side effects to the FDA at 1-800-FDA-1088.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
This appears to be a statistical data table showing cumulative incidence (%) along with hazard ratio (HR) and p-value. The data indicates a decline in cumulative incidence over time and provides specific values for different time points. The hazard ratio of 0.84 suggests a decrease in the risk of the event being studied, with a statistically significant p-value of 0.0005.*
FDA Label Image

Figure_2 (Figure 2)

Figure_2 (Figure 2)
Cumulative Hazard for placebo group and Atorvastatin group (HR 0.63, 95% CI 0.48-0.83, p=0.001) in a study of time to first primary endpoint over four years of follow-up.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
This text provides data on the percentage of subjects experiencing events while taking Atorvastatin at doses of 10 mg and 80 mg, with reference to a study identified as HRO78(060089). It also mentions a statistical analysis result (P=0.0002) related to the time to the first major cardiovascular endpoint in years.*
FDA Label Image

Structure (Structure)

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.